Drugs / SLx-4090
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01675154 | Nov 2015 → Jun 2020 | hyperlipoproteinemia, type 1D | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT02434744 | Apr 2015 → Mar 2016 | type 2 diabetes mellitus | Response Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00871936 | Apr → Oct 2009 | type 2 diabetes mellitus | Response Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00810979 | Jan → Sep 2009 | hyperlipidemia | Response Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00562575 | May 2007 → Feb 2008 | hypertriglyceridemia | Response Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLx-4090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00810979 ↗ |
| Known as | KD026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02434744 ↗ |
| Action | Inhibit | “an intestinal-specific inhibitor of microsomal triglyceride transport protein (MTP)” NCT01675154 ↗ |
| Modality | Small molecule | — CHEMBL4297326 ↗ |
| Route | Oral | “oral doses of SLx-4090” NCT00562575 ↗ |